WEBULL
WebtradeDownload

Does Phase 1 Drug Cancellation Change The Bull Case For Nurix Therapeutics (NRIX)?

Simply Wall St · 2d ago
  • Sanofi informed Nurix Therapeutics that it has discontinued the Phase 1 trial of SAR448272 and terminated the STAT6 degrader program, removing any future milestone or royalty income from this asset.
  • The end of SAR448272 shifts the economic weight of Nurix Therapeutics' pharma partnerships toward remaining Sanofi licensed programs and other collaborators, increasing reliance on how those pipelines progress.
  • We will now look at how Nurix Therapeutics' investment narrative could shift as Sanofi walks away from the SAR448272 program.

Benchmark your thesis on Nurix Therapeutics against other potential opportunities by scanning our curated list of 19 high quality undiscovered gems with similar under-the-radar partnership stories and risk profiles.

Nurix Therapeutics Investment Narrative Recap

To own Nurix Therapeutics, you have to believe the degrader platform and partnered pipeline can offset lumpier collaboration income and high R&D spend over time. The loss of SAR448272 removes a potential stream of future Sanofi milestones and royalties, which tightens the focus on how bexobrutideg and IRAK4 progress.

In the near term, the clearest catalyst is execution with Roche on bexobrutideg across oncology and autoimmune indications. The biggest operational risk remains that larger studies fail to echo early response rates or that external funding and partnership flows do not adequately cover ongoing operating losses if one time payments soften.

The Roche bexobrutideg partnership now matters even more in light of Sanofi stepping away from SAR448272. That alliance includes a US$700 million upfront payment, up to US$2.3 billion in milestones, a 50:50 U.S. cost and profit share, and ex U.S. royalties that can partially offset lost optionality from Sanofi on STAT6.

For shareholders, execution around the broad bexobrutideg development plan in CLL, lymphoma, chronic spontaneous urticaria and multiple sclerosis is the practical swing factor. Trial momentum, the timing of any further Roche related receipts and progress with the Gilead partnered IRAK4 degrader now carry more weight in Nurix Therapeutics' story.

Nurix Therapeutics' narrative projects US$297.9 million in revenue and US$47.6 million in earnings by 2029. This assumes revenue decreases by 24.9% per year and earnings decline by about US$247.3 million from US$294.9 million today.

Uncover why Nurix Therapeutics' fair value indicates a 125% potential upside to its current price that could narrow quickly.

NasdaqGM:NRIX 1-Year Stock Price Chart
NasdaqGM:NRIX 1-Year Stock Price Chart

Exploring Other Perspectives

Some of the most optimistic analysts focused on STAT6 as a key upside catalyst for Nurix Therapeutics, with forecasts before this Sanofi decision that revenues could reach about US$466.0 million and earnings about US$8.2 million by 2029. You now have fresh information they did not have, so treat those projections as moving targets and compare several viewpoints.

Explore 2 other Nurix Therapeutics fair value estimates, including one that suggests as much as 228% upside from the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider trusting your own analysis.

Looking For More Investment Ideas Beyond Nurix Therapeutics?

Once you have a handle on Nurix Therapeutics, it can help to widen the lens and compare it with other companies that share similar risk and reward trade offs. The Simply Wall St Screener lets you quickly surface different types of opportunities that might better match your time horizon, volatility comfort, or focus on quality.